OncoMatch/Clinical Trials/NCT04698252
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer
Is NCT04698252 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Estrogen receptor-positive and/ or progesterone receptor-positive breast cancer
Required: PR (PGR) positive
Estrogen receptor-positive and/ or progesterone receptor-positive breast cancer
Excluded: HER2 (ERBB2) positive
HER2-positive breast cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Partial response or stable disease after at least six months of systemic therapy for breast cancer
Cannot have received: local therapy for distant metastasis
Previous local therapy for distant metastasis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify